Short- and long-term follow-up and additional benefits in a sickle cell disease patient experienced severe crizanlizumab infusion-related vaso-occlusive crisis: A case report
Sickle cell disease is an autosomal recessive disorder characterized by the presence of sickle hemoglobin that leads to chronic hemolysis and vaso-occlusive crisis. After decades of limited therapy options, crizanlizumab is a humanized monoclonal antibody approved by the Food and Drug Administration...
Na minha lista:
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2022-11-01
|
| coleção: | Frontiers in Medicine |
| Assuntos: | |
| Acesso em linha: | https://www.frontiersin.org/articles/10.3389/fmed.2022.1048571/full |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|